Oxytocin Treatment of Schizophrenia
Summary
Purpose: Test whether intranasal administration of the neuropeptide, oxytocin, improves social cognition, social functioning and decreases paranoia and other psychotic symptoms in schizophrenia. Participants: Up to 80 adults with schizophrenia for at least one year and with a high rating for paranoia. Procedures (methods): Oxytocin or placebo will be administered twice daily in an intranasal spray (6 insufflations/dose or 24 IU) for 6 weeks. Before, during and at the end of the trial, each subject will undergo social cognitive measures (primary outcomes) and psychiatric symptom ratings (secondary outcomes).
Timeline
- Start
- 2009-11
- Primary completion
- 2011-03
- Completion
- 2011-03
Outcome
Missed primary endpoint
registry analysis (superiority or other test); Intranasal Spray With Oxytocin; p = .61; t-test, 1 sided; note: Not adjusted for multiple comparisons NCT01028677 ↗
registry analysis (superiority or other test); Intranasal Spray With Oxytocin vs Intranasal Spray Without Oxytocin; p = .03; t-test, 2 sided NCT01028677 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oxytocin | Peptide | 24 iu | Intranasal |